Northland Securities analyst James Terwilliger maintained a Buy rating on Cardiovascular Systems (NASDAQ:CSII) on Monday, setting a price target of $45, which is approximately 18.05% above the present share price of $38.12.
Terwilliger expects Cardiovascular Systems to post earnings per share (EPS) of -$0.15 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Cardiovascular Systems, with an average price target of $47.2.
The analysts price targets range from a high of $50 to a low of $43.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $63.27 million and a net profit of -$5.65 million. The company's market cap is $1.53 billion.
According to TipRanks.com, Northland Securities analyst James Terwilliger is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 19.1% and a 75.61% success rate.
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. Its products are catheter-based platforms capable of treating a range of vessel sizes and plaque types. The company was founded in 2000 and is headquartered in St. Paul, MN.